Exercise programs with higher intensity levels result in better outcomes for patients
the ONA take:
A supervised, moderate- to high-intensity exercise program that combines resistance and aerobic exercise (eg, OnTrack) is most effective for patients with breast cancer undergoing adjuvant chemotherapy.
However, a home-based, low-intensity physical activity program (eg, Onco-Move) provides some benefit and is a viable alternative for women who cannot or will not participate in more intensive exercise compared with usual care (UC).
In this study, 230 women who were scheduled to undergo adjuvant chemotherapy were randomly assigned to Onco-Move, OnTrack, or (UC). Assessments were made before assignment, at the end of chemotherapy, and at the 6-month follow-up.
Cardiorespiratory fitness, physical functioning, nausea and vomiting, and pain outcomes were all better in the intervention groups compared with the UC group.
Those in the OnTrack group also had better muscle strength and less physical fatigue, plus a smaller percentage of them needed dose adjustments.
In addition, patients in both intervention groups returned earlier, as well as for more hours per week, to work than patients in the UC group.
A supervised, moderate- to high-intensity exercise program is most effective for patients with breast cancer undergoing adjuvant chemotherapy.
Sign Up for Free e-newsletters
- Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Molecular Features May Predict Response in Primary Pancreatic Cancer
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Clinical Characteristics That Increase Risk of Chemotherapy-Induced Febrile Neutropenia Identified
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Counseling Patients on Oral Chemotherapy
- Patients and Caregivers Worry About Cost of Cancer Care
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|